FDA issued 21 new and 16 revised product-specific draft guidances for generic drug development. To successfully develop and manufacture a generic drug product, the product is expected to be pharmaceutically equivalent to its reference listed drug (RLD). Some of the CDER OGD guidances include discussion regarding data formats.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
